Identification of Targetable <i>EGFR</i> Mutations in Ovarian Cancer
Ovarian cancer driven by an oncogenic <i>EGFR</i> mutation is a rare occurrence, yet it is an actionable molecular target with EGFR-directed inhibitors. This underlies the potential value of comprehensive NGS in the management of ovarian cancer for discovering actionable genomic alterations.
Authors
- Arjan Gower (ORCID: https://orcid.org/0000-0002-3361-9286)
- Shwe Win
- Amy L. Cummings (ORCID: https://orcid.org/0000-0003-0472-392X)
- Brian Di Carlo
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Maria A. Velez (ORCID: https://orcid.org/0000-0001-5197-4719)
- Edward B. Garon (ORCID: https://orcid.org/0000-0001-7077-8801)
- Aaron Elliott Lisberg (ORCID: https://orcid.org/0000-0003-3048-4352)
- Rituparna Ganguly
Institutions
- University of California, Los Angeles (US)
- Sarah Cannon (US)
- Caris Life Sciences (United States) (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1200/po-25-00390
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00